March 08, 2024

MindMed Soars on FDA Breakthrough Therapy Designation for “Truly Remarkable” Anxiety Candidate, Announces Capital Raise

Mind Medicine Inc. (Nasdaq: MNMD) has been granted FDA Breakthrough Therapy Designation for its generalized anxiety disorder (GAD) treatment candidate, MM120 (lysergide d-tartrate). MindMed also announced this week that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity. The… [Read More]
March 08, 2024

Immuron’s Travelan® Takes on Travel Sickness; Shares Soar Nearly 200%

Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has announced positive interim topline results from its study of Travelan® in preventing moderate to severe diarrhea following an enterotoxigenic Escherichia coli(ETEC) infection. The study supports the excellent safety and tolerability profile of Travelan®, and demonstrated that a single daily dose offered protective efficacy in healthy subjects challenged… [Read More]
March 08, 2024

Inhibikase Presents Update on Parkinson’s Disease Treatment Trial

Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than one million people in the US alone. Inhibikase Therapeutics (Nasdaq: IKT) is developing risvodetinib for the treatment of Parkinson’s disease through its 201 Trial and will present an update at the 2024 AD/PD conference being held in Lisbon, Portugal this week…. [Read More]
March 08, 2024

PRISM NextGen Tech & AI Index: LivePerson Delivering AI-empowered Customer Care

Shares in LivePerson (Nasdaq: LPSN) rose by nearly 22% during Thursday’s session after the company announced it had been named a notable vendor in leading independent research firm, Forrester’s, new report, titled “The Digital Customer Interaction Solutions Landscape, Q1 2024.” Forrester’s report covers the use of digital customer interaction solutions for orchestration, AI, and asynchronous… [Read More]
March 08, 2024

SciSparc Initiates Clinical Trial with First Patient Enrollment for Autism Spectrum Disorder Treatment in Children

SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focusing on treatments for central nervous system disorders, has recently initiated a clinical trial for autism spectrum disorder (ASD) by enrolling its first patient. The trial aims to assess the safety and effectiveness of SCI-210 in treating children aged between 5 and 18 years with ASD. This… [Read More]
March 07, 2024

Soluna (SLNH) Has Begun Preparations at Project Sophie, Its First AI Hosting Deal. Provides Business Update.

Today the leading developer of green data centers, Soluna Holdings, (SLNH) provided a business update and its monthly operating metrics for February. One of its highlights mentions they have begun making preparations at Project Sophie, its first AI hosting deal. Other notable highlights include a new noteholder amendment that will increase fundraising flexibility and reinforce… [Read More]
March 07, 2024

PRISM Market Moves on Thursday: The Honest Co. up, Novo Nordisk Shines; Shake Shack Upgraded, Victoria’s Secret Stumbles

US equities are trading higher at midday on Thursday, building on Wednesday’s gains. Outperformers include semis, social media, cloud software, homebuilders, banks, grocers, and select GLP-1 drug developers, while department stores, casual diners, cruise lines, A&D, payment processors, and biotech are having a more difficult day. Treasuries are mixed, the Dollar index is down (0.4%),… [Read More]
March 07, 2024

Nexalin Tackles Sleepless Nights with Insomnia Device; Shares Surge 48%

Shares in Nexalin Technology (Nasdaq: NXL) rose almost 50% in intraday trading on Wednesday after the company announced positive topline results from its clinical study evaluating its Gen-2 tACS device (tACS) for the treatment of chronic insomnia. Insomnia is one of the most common sleep disorders and affects approximately 6%–10% of adults worldwide. Commenting on… [Read More]